Summary
Background
Administration of convalescent plasma may serve as an adjunct to supportive treatment to prevent COVID-19 progression and death. We aimed to evaluate the efficacy and safety of 2 volumes of intravenous convalescent plasma (CP) with high antibody titers for the treatment of severe cases of COVID-19.
Methods
We conducted a Bayesian, randomized, open-label, multicenter, controlled clinical trial in 7 Brazilian hospitals. Adults admitted to hospital with positive RT-PCR for SARS-CoV2, within 10 days of the symptom onset, were eligible. Patients were randomly assigned (1:1:1) to receive standard of care (SoC) alone, or in combination with 200 mL (150–300 mL) of CP (Low-volume), or 400 mL (300–600 mL) of CP (High-volume); infusion had to be performed within 24 h of randomization. Randomization was centralized, stratified by center. The primary outcome was the time until clinical improvement up to day 28, measured by the WHO ten-point scale, assessed in the intention-to-treat population. Interim and terminal analyses were performed in a Bayesian framework. Trial registered at ClinicalTrials.gov: NCT04415086.
Findings
Between June 2, 2020, and November 18, 2020, 129 patients were enrolled and randomly assigned to SoC (n = 42), Low-volume (n = 43) or High-volume (n = 44) CP. Donors presented a median titer of neutralizing antibodies of 1:320 (interquartile range, 1:160 to 1:1088). No evidence of any benefit of convalescent plasma was observed, with Bayesian estimate of 28-day clinical improvement of 72.7% (95%CI, 58.8 to 84.7) in the SoC versus 64.1% (95%ci, 53.8 to 73.7) in the pooled experimental groups (mean difference of -8.7%, 95%CI, -24.6 to 8.2). There was one case of cutaneous mild allergic reaction related to plasma transfusion and one case of suspected transfusion-related acute lung injury but deemed not to be related to convalescent plasma infusion.
Interpretation
In this prospective, randomized trial of adult hospitalized patients with severe COVID-19, convalescent plasma was not associated with clinical benefits.
Funding
Brazilian Ministry of Science, Technology and Innovation, Fundação de Amparo à Pesquisa do Estado de São Paulo.
【저자키워드】 COVID-19, convalescent plasma, SARS-CoV-2, 【초록키워드】 Treatment, neutralizing antibody, SARS-CoV2, Bayesian, Open-label, randomization, severe COVID-19, hospital, technology, randomized trial, acute lung injury, hospitals, Randomized, Patient, Antibody titer, death, Clinical improvement, Mild, Efficacy and safety, multicenter, funding, positive RT-PCR, Combination, Innovation, Plasma transfusion, intravenous, no evidence of, Science, Standard of care, symptom onset, Volume, COVID-19 progression, interquartile range, Supportive treatment, Primary outcome, 95%CI, Controlled clinical trial, intention-to-treat population, clinical benefits, experimental group, Registered, allergic, Severe case, mean difference, finding, SOC, Bayesian framework, Prevent, benefit, median titer, Randomly, enrolled, performed, evaluate, conducted, hospitalized patient, analysis, the WHO, assigned, stratified, receive, eligible, Interim, 【제목키워드】 clinical trial, Bayesian, Open-label, Randomized, multicenter, severe COVID-19 patient,